Physician profile
Rajat Chander
NPI 1962551036
$8,277.56
in general payments reported to CMS, 2019-2025
26 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $1,012 · 2022: $1,959 · 2023: $2,924 · 2024: $982 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Consulting Fee: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.84 |
| Consulting Fee | $2,096.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,372.89 | 2022-2024 | Dupixent |
| Genzyme Corporation | $1,612.57 | 2022-2025 | |
| Micro-Tech Endoscopy USA, INC. | $900.00 | 2020 | |
| Abbvie INC. | $878.04 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Boston Scientific Corporation | $493.62 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.23 | 2019-2024 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $296.60 | 2024-2025 | Voquezna |
| Pfizer INC. | $231.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.75 | 2019-2025 | Entyvio |
| Braintree Laboratories, INC. | $116.14 | 2019-2023 | Sutab, Suflave |
| Qol Medical, LLC | $111.96 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $107.38 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $105.51 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $80.69 | 2020-2025 | Tremfya, Stelara |
| Celgene Corporation | $66.35 | 2023-2024 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $63.35 | 2025 | |
| Romark Laboratories, Lc | $57.13 | 2019 | |
| Intercept Pharmaceuticals, INC. | $38.66 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $27.57 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $27.03 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $26.97 | 2019-2023 | Dificid |
| Janssen Pharmaceuticals, INC | $25.85 | 2019 | |
| Ucb, INC. | $21.39 | 2020 | |
| Exact Sciences Corporation | $20.47 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.62 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $13.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.